May 2019: Changes to Reference Ranges & Test Builds

Special Communication

May 2019: Changes to Reference Ranges & Test Builds

Changes to Reference Ranges

Effective May 21, 2019.

Reference Ranges:

Cysticercus IgG Ab, Serum (CYSGBL)

≤ 0.8 IV:
Negative
No significant level of cysticercosis IgG antibody detected

0.9 – 1.1 IV:
Equivocal
Questionable presence of cysticercosis IgG antibody detected; repeat testing in 10-14 days may be helpful

≥ 1.2 IV:
Positive
IgG antibodies to cysticercosis detected, which may suggest current or past infection

Effective June 3, 2019.

Reference Ranges:

Liver Fibrosis, FibroTest-ActiTest (LIVFIB)

Apolipoprotein A1

Male:
≥ 115 mg/dL

Female:
≥ 125 mg/dL

Effective June 4, 2019.

Reference Ranges:

Galactose Quant, Plasma (GALAC)

≤ 7 days:
< 5.4 mg/dL

8 – 14 days:
< 3.6 mg/dL

≥ 15 days:
< 2.0 mg/dL

Effective July 2, 2019.

Reference Ranges:

Hemoglobin, A2 (HBA2)

Reference Range
2.0 – 3.1%

Effective July 2, 2019.

Reference Ranges:

Hemoglobin, A2 and F (A2F)

Hemoglobin Fetal:
0.0 – 0.9%

Hemoglobin A2 Percent:
2.0 – 3.1%

Effective July 2, 2019.

Reference Ranges:

Hemoglobin, Fetal (HBF)

Reference Range
0.0 – 0.9%

Effective July 9, 2019.

Reference Ranges:

Vancomycin (VANCRA)

0 – 99 Years:
10.0 – 20.0 µg/mL

Test Build Changes

These updates may require changes to the Test Build for interfaced clients.

Spinal Muscular Atrophy Carrier Screening and Diagnostic (SMAGEN)

Effective May 30, 2019.

Paraneoplastic Autoantibody Evaluation, CSF (PARCSF)

Effective June 11, 2019.

Discontinued Tests

Effective May 21, 2019.

Degradation Products (FDP)

Due to the lack of availability of the appropriate tubes, this test has been discontinued.

We suggest ordering D-Dimer (DDMER).

Any additional information will be included in a future Technical Update.  If you have any questions about these changes, please contact Client Services for assistance.

Special Communications
Immediate Test Changes
News & Updates